This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SOUTH SAN FRANCISCO, Calif. (
TheStreet) -- U.S. regulators have approved
Onyx Pharmaceuticals'(ONXX) multiple myeloma drug Kyprolis.
Onyx shares rose 12% to $76.47 in late Friday trading.
Kyprolis will be used to treat patients with multiple myeloma that is no longer responding to other therapies, including
Celgene's(CELG - Get Report) Revlimid or Thalomid and
Onyx will be ready to launch the drug on Aug. 1. One 28-day treatment cycle of Kyprolis therapy will cost $9,950, higher than what the Street was expecting. Patients in the Kyprolis clinical trial were on drug about 4.4 months, Onyx said.
"The approval of Kyprolis provides a treatment option to patients with multiple myeloma whose disease has progressed despite use of available therapies," said FDA's cancer drug chief Richard Pazdur, in a statement. "We are encouraged by the continued progress in the development of drugs for multiple myeloma over the past decade, offering improved treatment of this disease."
"Today's approval is a significant milestone for Onyx and, most importantly, for patients with advanced myeloma who have few treatment options available to them," said Onyx CEO Tony Coles, in a statement.
Ligand Pharmaceuticals(LGND - Get Report) will receive a royalty on Kyprolis sales. Ligand shares were down 11 cents to $17.42 in recent trading.
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to:
Twitter and become a fan on